a16z Podcast: Players and Paths for Healthcare Startups
The creation of each new biotechnology enables a tool, a therapy, or a diagnostic: a molecule, a protein, an app, a platform. And the process underneath isn't just complex in the science and engineering of it, but in the go to market. So who are the stakeholders in this process? In this podcast (which was originally…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The a16z Show
See all episodes →
Similar episodes from other shows
More like The a16z Show →
Andreessen Horowitz's Vijay Pande: "AI doctors"
The Healthcare Outlook: Macro Challenges and Biotech Innovations
D.A. Wallach Explains Why Biotech VC Is So Different
20VC: a16z's David George on Leading a16z's Growth Fund Today, The Biggest Misconceptions of Growth Investing, How a16z Think Through Portfolio Construction, Investment Decision-Making and Scenario Planning & How The Entrance of New Players Has Changed Th
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.